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Economic Burden of Cancer in Korea during 2000-2010
Purpose
This study estimated the economic burden of cancer in Korea during 2000-2010 by cancer
site, gender, age group, and cost component. 
Materials and Methods
Data came from national health insurance claims data and information from Statistics
Korea. Based on the cost of illness method, this study calculated direct, morbidity and 
mortality cost of cancer in the nation during 2000-2010 by cancer site, gender, and age
group. 
Results
With an average annual growth rate of 8.9%, the economic burden of cancer in Korea 
increased from 11,424 to 20,858 million US$ (current US dollars) during 2000-2010. 
Colorectal, thyroid, and breast cancers became more significant during the period, i.e., the
5th/837, the 11th/257, and the 7th/529 in 2000 to the 3rd/2,210, the 5th/1,724, and
the 6th/1,659 in 2010, respectively (rank/amount in million US$ for the total population).
In addition, liver and stomach cancers were prominent during the period in terms of the
same measures, i.e., the 1st/2,065 and the 2nd/2,036 in 2000 to the 1st/3,114 and the
2nd/3,046 in 2010, respectively. Finally, the share of mortality cost in the total burden
dropped from 71% to 51% in Korea during 2000-2010, led by colorectal, thyroid, breast,
and prostate cancers during the period. These results show that the economic burden of
cancer in Korea is characterized by an increasing importance of chronic components. 
Conclusion
Incorporation of distinctive epidemiological, sociocultural contexts into Korea’s cancer con-
trol program, with greater emphasis on primary prevention such as sodium-controlled diet
and hepatitis B vaccination, may be needed. 
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Introduction
Cancer burden is expected to show a rapid growth with
the aging population and increasing cancer incidence [1-6].
The share of elders (or those aged 65 years or older) in the
United States increased from 10.0% in 1972 to 12.7% in 2008,
whereas the share for South Korea (Korea hereafter) 
registered a similar but steeper trend, i.e., 7.3% in 2000 to
11.1% in 2010 [1]. America’s age-standardized incidence rate
per 100,000 for all cancers rose from 400 in 1975 to 472 in 2004
[2], while the statistic for Korea went up from 205 in 2000 to
286 in 2010 [3]. As a result, the share of direct cost for cancer
care in the United States economy doubled from 0.32% in
1972 to 0.66% in 2008 [1,4,5]. Likewise, the population-health
burden of cancer in Korea (disability-adjusted life years per
100,000) showed a rapid growth from 1,109 person-years in
2000 to 1,681 person-years in 2010 [6]. As cancer burden 
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increases rapidly, a burden-of-cancer study designed to 
improve the quality of patient life and to set up national 
priorities for resource allocation in health services becomes
more essential. 
Based on previous studies, a large part of cancer burden
in an advanced nation comes from breast, colon, lung, and
prostate cancers [7-9]. In terms of direct cost (national dollars,
million), these cancers ranked in the top four in the United
States for 1996 (5,980, 5,710, 4,680, and 4,610) [7], Canada for
1998 (120, 216, 228, and 103) [8] and New South Wales in
Australia for 2004 (77, 132, 77, and 121) [9]. Other research
has shown that as medical technology advanced and cancer
survival increased, the share of income loss from premature
death in cancer burden gradually fell in the developed world
[4-5,7,10-13]. The share in the United States, which was 73%
in 1972 [4], decreased to 61% in 1990 [7], dipping further to
51% in 2008 [5]. Likewise, the number in Sweden went down
from 45% in 2000 to 39% in 2004 [10]. However, based on 
recent reviews, most existing literature on national economic
burden has been limited to direct medical cost and compre-
hensive examination on national economic burden by cancer
site, gender, age group, and cost component over a long time
span has been limited [10,11]. 
Some researchers have estimated economic burden for
major cancers in Korea for 2002 and 2005 [12,13]. According
to their findings, liver, stomach, and lung cancers led the 
nation’s cancer burden, with the costs of 1,749, 1,784, and
1,289 million US$ in 2002 and 2,387, 2,321, and 1,614 million
US$ in 2005, respectively (or the shares of 18.6%, 18.9%, and
13.7% in all cancers for 2002 and 17.4%, 16.9%, and 11.7% 
for 2005, respectively) [12,13]. However, cancers that are
prevalent in other developed nations, including breast, colon,
and prostate cancers, are becoming more common in Korea,
a nation characterized by rapid westernization in health 
behavior in the past two decades [3]. In addition, Korea is
becoming an aging society populated by one of the greatest
proportions of elderly by 2020 [14]. With such significant
transitions, updating the estimation of economic burden for
major cancers in Korea during the period 2000-2010 will not
only provide invaluable opportunities for designing the 
nation’s healthcare policies for the future, but will also be
helpful in establishing the direction of future study for other
nations with similar transformations. In this vein, this 
research involves a comprehensive examination of cancer
burden in Korea during 2000-2010, i.e., by cancer site, gender,
age group, and cost component.
Materials and Methods
This study uses the cost of illness (COI) method [7-9,12,13]
to estimate the economic burden of cancer in Korea during
2000-2010 by cancer site, gender, and age group. Based on
the COI classification, the economic burden of disease 
consists of three components, i.e., direct, morbidity, and 
mortality cost. Direct cost is “expenditure for medical 
services associated with the treatment and care of the disease
entity” whereas (indirect) morbidity/mortality cost is 
“productivity loss due to disability/premature death associ-
ated with the disease entity” [7]. 
Table 1 shows components, formulas, and data sources for
the economic burden of cancer in Korea during 2000-2010.
Direct cost includes medical cost covered by health 
insurance, medical cost uncovered, transportation cost, 
caregiver cost and cost for alternative medicine. Data on
medical cost (covered for hospitalization, outpatient visit,
and drug prescription) came from national health insurance
claims data [15] (the most representative health data in Korea
given that the Korean government launched a compulsory
national health insurance program for the entire population
in Y1989 [12]). Medical cost uncovered was derived from 
national surveys on out-of-pocket expenditure of patients 
enrolled in health insurance [16]. For calculation of 
transportation cost, the number of outpatient visit days [15]
was multiplied by transportation cost per outpatient visit
day (4.9 US$ [or $4.9 hereafter] in 2002 [12] before being 
adjusted for inflation [17]). This value was multiplied by 2
(with an assumption that a family member would be present
for each outpatient visit [12]). For the estimation of caregiver
cost, its “inpatient” and “outpatient” parts were calculated
and then combined. Regarding the former part, the number
of inpatient days [15] was multiplied by caregiver cost per
inpatient day ($50 in 2002 [12] before being adjusted for 
inflation [17]). Regarding the latter part, the number of 
outpatient visit days [15] was multiplied by 4 (the number
of hours per outpatient visit) [12] and caregiver cost per 
outpatient visit hour ($9.3 in 2002 [12] before being adjusted
for inflation [17]). For calculation of cost for alternative 
medicine, the number of patients [15] was multiplied by cost
for alternative medicine per patient ($1,150 in 2002 [12] 
before being adjusted for inflation [17]) (Table 1).
Morbidity and mortality costs were derived based on a
human capital approach, which assumes that the monetary
value of productivity loss equals the current wage 
[7-9,12,13,18]. It was assumed that those younger than 15 or
older than 69 did not work [12,13]. For calculation of 
morbidity cost, productivity loss due to cancer-specific 
disability “inside” and “outside” the labor market were 
estimated and then combined. Regarding the former loss, the
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Table 1. Cancer burden: components, formulas, and data sources
Component / Formula Data source
Direct cost 
Medical, covered (MC) 
i/j Gender (M, F)/age group index 
MC1ij MC hospitalization [15] 
MC2ij MC outpatient visit [15] 
Formula !ij (MC1ij+MC2ij) [12] 
Medical, uncovered (MU) 
R1 MU1/(MC1+MU1) hospitalization [16] 
R2 MU2/(MC2+MU2) outpatient visit [16] 
MU1ij MC1ij*[R1/(1–R1)] [15,16] 
MU2ij MC2ij*[R2/(1–R2)] [15,16] 
Formula !ij(MU1ij+MU2ij) [13] 
Transportation 
Tij Transportation cost per visit day $4.9 in 2002 [12]  
D2ij Outpatient visit days [15] 
2 Factor from family member’s visit [12] 
Formula !ij Tij*D2ij*2 Inflation [12,17] 
Caregiver 
C1ij Caregiver cost per inpatient day $50 in 2002 [12]
D1ij Inpatient days [15] 
C2ij Caregiver cost per visit hour $9.3 in 2002 [12] 
4 Hours per outpatient visit [12] 
D2ij Outpatient visit days [15] 
Formula !ij(C1ij*D1ij)+!ij(C2ij*4*D2ij) Inflation [12,17] 
Alternative medicine (AM) 
AMij AM cost per patient $1,150 in 2002 [12] 
Pij Patients [15] 
Formula !ij AMij*Pij Inflation [12,17] 
Indirect cost 
Morbidity 
Wij Yearly wage (WFj: for women) [17] 
Pij Patients [15] 
Aij Participation rate for economic activity [17] 
Eij Employment rate [17] 
L1 Patient’s job loss rate 0.51 [13] 
H Participation rate for housework 0.67 [13] 
L2 Patient’s housework loss rate 86.5/365.0 days [13] 
Formula !ijWij*Pij*Aij*Eij*L1+ [13]
!j WFj*PFj*(1–AFj)*H*L2
Mortality 
k Year Index (t+1, t+2,… , t+70 - j) -
Mij Mortalities at year t [17] 
w Average annual wage growth rate 0.08 for 2000-2010 [17] 
Wijk Wij at year t+k [or Wij*(1+w)k] [17] 
Aijk Aij at year t+k [or Ai,j+k] [17] 
Eijk Eij at year t+k [or Ei,j+k] [17] 
H H at year t+k [or H] 0.67 [13] 
r Discount rate 0.03 [13]  
Formula !ijMij{!k [(Wijk*Aijk*Eijk)/(1+r)k]}+ [13] 
!j MFj{!k [WFjk*(1–AFjk)*H/(1+r)k]}
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yearly wage (or productivity loss) [17] was multiplied by the
number of patients [15], the participation rate for economic
activity [17], the employment rate [17], and the rate of job
loss for the cancer patient (0.51) [13] (the participation rate
for economic activity and the employment rate vary by 
gender, age group, and year). Regarding the latter loss,
women’s yearly wage (or productivity loss) [17] was multi-
plied by the number of female patients [15], women’s 
non-participation rate for economic activity [17], women’s
participation rate for housework (0.67) [13], and the rate of
housework loss for the female cancer patient (86.5
days/365.0 days) [13] (The women’s non-participation 
rate for economic activity varies by age group and year).
Likewise, for calculation of mortality cost, productivity 
loss due to cancer-specific premature death “inside” and 
“outside” the labor market were estimated and then 
combined. Regarding the former loss, the number of mortal-
ities [17] was multiplied by the expected value of the future
income during potential years of life lost [17] with a discount
rate (0.03) [13]. Regarding the latter loss, the number of
women’s mortalities [17] was multiplied by the expected
value of women’s opportunity cost (for housework) during
potential years of life lost [13,17] with a discount rate (0.03)
[13]. For calculation of the expected value of the future 
income or women’s opportunity cost for housework during
potential years of life lost from a base year (e.g., 2010), it was
assumed that (1) the participation rate for economic activity
and the employment rate (varying by gender and age group
in a given year) stay the same in the future as in the base year
and (2) the women’s non-participation rate for economic 
activity (varying by age group in a given year) remains the
same in the future as in the base year.
Table 2. Number of cancer patients in Korea by cancer site and gender in 2000 and 2010
Cancer type ICD-10 Men Women Total Rank for totalcode 2000 2010 2000 2010 2000 2010 2000 2010
Thyroid C73 14,382 59,191 31,237 137,299 45,619 196,490 5 1
Stomach C16 59,491 87,846 32,430 47,156 91,921 135,002 1 2
Colorectum C18-C21 32,420 65,443 27,001 51,922 59,421 117,365 2 3
Breast C50 600 996 42,005 96,511 42,605 97,507 6 4
Lung C33-34 37,243 38,226 15,659 16,071 52,902 54,297 4 5
Liver C22 41,348 38,657 15,813 15,151 57,161 53,808 3 6
Prostate C61 9,881 36,105 0 0 9,881 36,105 14 7
Kidney C64 6,465 18,412 3,390 10,170 9,855 28,582 15 8
Uterine cervix C53 0 0 27,990 28,021 27,990 28,021 7 9
Bladder C67 9,089 16,075 2,585 5,011 11,674 21,086 12 10
NHL C82-C85 5,570 4,944 11,691 11,627 17,261 16,571 8 11
Ovary C56 0 0 16,403 14,542 16,403 14,542 9 12
Mouth C00-C14 9,224 7,647 6,515 5,559 15,739 13,206 10 13
Brain C69-C72 5,690 6,333 5,611 6,088 11,301 12,421 13 14
Leukemia C91-C95 4,516 6,500 4,127 5,904 8,643 12,404 17 15
Pancreas C25 5,700 6,001 4,139 4,687 9,839 10,688 16 16
Uterus C54-C55 0 0 4,209 9,989 4,209 9,989 21 17
Skin C43-C44 2,262 4,800 2,523 5,053 4,785 9,853 20 18
Esophagus C15 5,979 5,990 1,092 1,067 7,071 7,057 18 19
Larynx C32 5,334 6,192 851 740 6,185 6,932 19 20
MM C90 1,522 2,390 1,258 1,965 2,780 4,355 22 21
Gallbladder C23-C24 7,832 1,605 6,602 1,402 14,434 3,007 11 22
Testis C60,62,63 1,722 1,747 0 0 1,722 1,747 23 23
HL C81 552 475 925 956 1,477 1,431 24 24
Others 7,372 7,958 6,152 6,923 13,524 14,881 
Total 274,194 423,534 270,208 483,813 544,402 907,347 
Source: Korea Health Insurance Corporation [15]. ICD-10, International Classification of Diseases 10th revision; NHL, 
non-Hodgkin lymphoma; MM, multiple myeloma; HL, Hodgkin lymphoma.
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Results
Tables 2 and 3 shows the number of patients (or mortali-
ties) in Korea by cancer site and gender in 2000 and 2010,
listed based on the rank in 2010. The total number of cancer
patients increased by 66.67%, from 544,402 to 907,347 during
2000-2010. The increase in cancer prevalence during the 
period was more pronounced for women than for men, with
the growth rate of 79.1% versus 54.5% (from 270,208 to
483,813 vs. from 274,194 to 423,534). Thyroid, breast, and
prostate cancers led this rapid growth of prevalence during
the period. For example, the rank/number of prevalence 
increased from the 5th/45,619 to the 1st/196,490 for thyroid
cancer, from the 6th/42,605 to the 4th/97,507 for breast 
cancer, and from the 14th/9,881 to the 7th/36,105 for prostate
cancer. It is also noteworthy that kidney and bladder cancers
entered the top ten during the period, i.e., the 15th/9,855 and
the 12th/11,674 in 2000 to the 8th/28,582 and the 10th/21,086
in 2010, respectively. On the contrary, the ranks/numbers of
prevalence for liver cancer, non-Hodgkin lymphoma, and
ovary cancer declined during the period, i.e., the 3rd/57,161,
the 8th/17,261, and the 9th/16,403 in 2000 to the 6th/53,808,
the 11th/16,571, and the 12th/14,542 in 2010, respectively.
Table 4 and Fig. 1 describe economic burden in Korea by 
cancer site and gender during 2000-2010 (with the shares of
mortality cost in parentheses for the table). In terms of 
the total burden for the total population (million $), liver,
stomach, and lung cancers ranked 1st (3,114), 2nd (3,046),
and 4th (1,988) in 2010 after holding the same positions in
2000 (2,065, 2,036, and 1,202). Colorectal cancer, a top five
(837) in 2000, replaced leukemia as a top three in 2010 (2,210).
Thyroid cancer, out of the top ten in 2000 (11th, 257), made
the top five in 2010 (1,724). Likewise, breast cancer, a top
seven (529) in 2000, became a top six (1,659) in 2010. A similar
trend was observed for men. In terms of the total burden,
liver, stomach, and lung cancers constituted the top three
both in 2000 (1,744, 1,332, and 881) and in 2010 (2,638, 2,090,
and 1,476). Colorectal cancer and leukemia, which ranked
5th (525) and 4th (790) in 2000, switched their positions in
Table 3. Number of cancer mortalities in Korea by cancer site and gender in 2000 and 2010 
Cancer type ICD-10 Men Women Total Rank for totalcode 2000 2010 2000 2010 2000 2010 2000 2010
Lung C33-C34 8,575 11,411 2,965 4,204 11,540 15,615 1 1
Liver C22 7,697 8,350 2,343 2,855 10,040 11,205 3 2
Stomach C16 7,434 6,512 4,069 3,520 11,503 10,032 2 3
Colorectum C18-C21 2,239 4,350 1,962 3,351 4,201 7,701 4 4
Pancreas C25 1,546 2,323 1,162 1,983 2,708 4,306 5 5
Gallbladder C23-C24 1,355 1,758 1,289 1,744 2,644 3,502 6 6
Breast C50 21 10 1,148 1,858 1,169 1,868 9 7
Leukemia C91-C95 789 922 574 696 1,363 1,618 8 8
NHL C82-C85 553 807 316 623 869 1,430 12 9
Esophagus C15 1,351 1,254 149 98 1,500 1,352 7 10
Prostate C61 545 1,328 0 0 545 1,328 18 11
Brain C69-C72 534 652 464 543 998 1,195 11 12
Bladder C67 588 822 182 278 770 1,100 13 13
Mouth C00-C14 661 742 393 221 1,054 963 10 14
Uterine cervix C53 0 0 726 956 726 956 15 15
Ovary C56 0 0 561 895 561 895 17 16
Kidney C64 337 562 175 235 512 797 19 17
MM C90 169 399 118 364 287 763 21 18
Larynx C32 651 383 109 33 760 416 14 19
Skin C43-C44 168 177 132 206 300 383 20 20
Thyroid C73 73 94 193 262 266 356 22 21
Uterus C54-C55 0 0 584 316 584 316 16 22
HL C81 156 46 91 35 247 81 23 23
Testis C60,62,63 38 20 0 0 38 20 24 24
Total 35,480 42,922 19,705 25,276 55,185 68,198 
Source: Korea Health Insurance Corporation [17]. ICD-10, International Classification of Diseases 10th revision; NHL, 
non-Hodgkin lymphoma; MM, multiple myeloma; HL, Hodgkin lymphoma.
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2010 (4th, 1,420 vs. 5th, 965). Thyroid cancer, out of the top
ten in 2000 (13th, 110), joined the top six in 2010 (707) (Tables
2-4, Fig. 1).
Some gender differences can be seen in Table 4, as breast
and thyroid cancers made the top two instead of liver and
stomach cancers for women’s total burden in 2010 (1,648,
1,017 vs. 477, 956). Economic burden in Korea by cancer site
and age group in 2000 and 2010 is described in Table 5. For
the age group 0-14 years old, leukemia, brain cancer, and
non-Hodgkin lymphoma led the total burden during 2000-
2010. For those aged 15 years or older, liver, stomach, 
colorectal, and lung cancers constituted the top four in both
2000 and in 2010. However, the former two were more 
dominant for the age group 15-69 years old, while the latter
two were more significant for those aged 70 years or older.
Indeed, the rise of colorectal cancer was more evident for the
older age group and the opposite was true for thyroid cancer.
Finally, Table 6 and Fig. 2 show the economic burden of 
cancer in Korea by cost component during 2000-2010. With
an average annual growth rate of 8.9%, the total burden 
(million $) increased from 11,424 to 20,858 during the period.
The share of mortality cost in the total burden dropped from
70.7% to 51.7% during 2000-2010, as the figures for most 
cancers fell by more than 10.0% during the period (Table 4,
Fig. 1). On the contrary, the shares of direct and morbidity
cost in the total burden rose during 2000-2010, from 5.6% to
14.7% for medical cost (covered), from 2.9% to 3.8% for 
medical cost (uncovered), from 0.2% to 0.4% for transporta-
tion cost, from 2.5% to 4.4% for caregiver cost, from 5.4% to
6.7% for the cost of alternative medicine, and from 12.8% to
18.3% for morbidity cost. Colorectal, thyroid, breast, and
prostate cancers led this rapid growth of direct and morbid-
ity cost during the period (Table 4, Fig. 1). For example, the
rank/amount of direct cost (million $) increased from the
4th/211 to the 1st/855 for colorectal cancer, from the 6th/120
to the 3rd/703 for thyroid cancer, from the 5th/131 to the
Table 4. Economic burden in Korea by cancer site, gender in 2000 and 2010 (million US$)
Cancer ICD-10 Men (M) Women (W) Total (T) Rank for total [M/W]
type code 2000 2010 2000 2010 2000 2010 2000 2010
Liver C22 1,744 (0.80) 2,638 (0.74) 322 (0.75) 477 (0.62) 2,065 (0.79) 3,114 (0.72) 1 [1/5] 1 [1/7]
Stomach C16 1,332 (0.67) 2,090 (0.51) 704 (0.78) 956 (0.61) 2,036 (0.71) 3,046 (0.54) 2 [2/1] 2 [2/3]
Colorectum C18-C21 525 (0.55) 1,420 (0.42) 312 (0.57) 790 (0.41) 837 (0.55) 2,210 (0.41) 5 [5/6] 3 [4/4]
Lung C33-C34 881 (0.69) 1,476 (0.57) 322 (0.76) 512 (0.63) 1,202 (0.71)  1,988 (0.58) 4 [3/4] 4 [3/5]
Thyroid C73 110 (0.08) 707 (0.02) 147 (0.07) 1,017 (0.01) 257 (0.07) 1,724 (0.01) 11 [13/10] 5 [6/2]
Breast C50 11 (0.68) 11 (0.05) 518 (0.57) 1,648 (0.38) 529 (0.57) 1,659 (0.37) 7 [21/2] 6 [21/1]
Leukemia C91-C95 790 (0.93) 965 (0.80) 433 (0.91) 521 (0.71) 1,223 (0.92) 1,475 (0.77) 3 [4/3] 7 [5/6]
Brain C69-C72 395 (0.88) 678 (0.84) 303 (0.89) 324 (0.78) 698 (0.89) 1,002 (0.82) 6 [6/7] 8 [7/10]
NHL C82-C85 260 (0.81) 416 (0.57) 133 (0.64) 236 (0.59) 394 (0.75) 649 (0.58) 8 [7/11] 9 [9/11]
Pancreas C25 210 (0.79) 420 (0.76) 95 (0.75) 198 (0.69) 304 (0.78) 618 (0.73) 9 [8/13] 10 [8/12]
Uterine cervix C53 0 (0.00) 0 (0.00) 257 (0.49) 448 (0.47) 257 (0.49) 448 (0.47) 12 [22/8] 11 [22/8]
Kidney C64 116 (0.62) 303 (0.32) 57 (0.75) 98 (0.30) 173 (0.67) 402 (0.31) 15 [12/15] 12 [10/15]
Ovary C56 0 (0.00) 0 (0.00) 179 (0.51) 364 (0.53) 179 (0.51) 364 (0.53) 14 [22/9] 13 [22/9]
Mouth C00-C14 134 (0.55) 253 (0.52) 48 (0.50) 85 (0.52) 182 (0.53) 338 (0.52) 13 [11/16] 14 [12/16]
Prostate C61 55 (0.21) 295 (0.11) 0 (0.00) 0 (0.00) 55 (0.21) 295 (0.11) 22 [16/23] 15 [11/23]
Gallbladder C23-C24 173 (0.67) 164 (0.84) 121 (0.71) 106 (0.84) 293 (0.69) 270 (0.84) 10 [9/12] 16 [15/14]
Bladder C67 81 (0.33) 182 (0.21) 16 (0.39) 39 (0.22) 98 (0.34) 220 (0.21) 17 [14/20] 17 [14/19]
Esophagus C15 142 (0.68) 183 (0.49) 17 (0.75) 15 (0.40) 159 (0.69) 198 (0.48) 16 [10/19] 18 [13/21]
MM C90 33 (0.61) 102 (0.48) 16 (0.49) 59 (0.35) 49 (0.57) 161 (0.43) 23 [19/21] 19 [16/18]
Skin C43-C44 46 (0.72) 81 (0.47) 22 (0.59) 66 (0.52) 68 (0.68) 147 (0.49) 21 [18/18] 20 [18/17]
Uterus C54-C55 0 (0.00) 0 (0.00) 91 (0.79) 140 (0.39) 91 (0.79) 140 (0.39) 18 [22/14] 21 [22/13]
Larynx C32 76 (0.57) 86 (0.31) 6 (0.48) 5 (0.14) 82 (0.57) 91 (0.30) 19 [15/22] 22 [17/22]
HL C81 49 (0.91) 31 (0.59) 28 (0.88) 20 (0.68) 77 (0.90) 52 (0.62) 20 [17/17] 23 [20/20]
Testis C60,62,63 31 (0.68) 42 (0.54) 0 (0.00) 0 (0.00) 31 (0.68) 42 (0.54) 24 [20/23] 24 [19/23]
Others 52 (0.00) 117 (0.00) 30 (0.00) 75 (0.00) 82 (0.00) 191 (0.00) 
Total 7,247 (0.72) 12,659 (0.56) 4,178 (0.68) 8,198 (0.46) 11,424 (0.71) 20,844 (0.52) 
Values in rounded parentheses are presented as share of mortality cost. ICD-10, International Classification of Diseases 10th
revision; NHL, non-Hodgkin lymphoma; MM, multiple myeloma; HL, Hodgkin lymphoma.
Kwang-Sig Lee, Economic Burden of Cancer in Korea
VOLUME 47  NUMBER 3  JULY  2015 393
0
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010
M
ill
io
n 
US
$
Direct cost (men)
Stomach
Colorectum
Lung
Liver
Thyroid
Prostate
Leukemia
NHL
Kidney
Bladder100
200
300
400
500
600
0
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010
M
ill
io
n 
US
$
Morbidity cost (men) 
Stomach
Thyroid
Colorectum
Liver
Lung
Kidney
Prostate
NHL
Bladder
Mouth100
200
300
400
500
600
0
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010
M
ill
io
n 
US
$
Mortality cost (men)
Liver
Stomach
Lung
Leukemia
Colorectum
Brain
Pancreas
NHL
Gallbladder
Mouth500
1,000
1,500
2,000
2,500
3,000
0
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010
M
ill
io
n 
US
$
Total burden (men)
Liver
Stomach
Lung
Colorectum
Leukemia
Brain
Pancreas
NHL
Kidney
500
1,000
1,500
2,000
2,500
3,000
3,500
0
100
200
300
400
500
600
700
800
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010
M
ill
io
n 
US
$
Direct cost (women)
Breast
Thyroid
Colorectum
Stomach
Lung
Liver
Uterine cervix
Ovary
NHL
0
100
200
300
400
500
600
700
800
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010
M
ill
io
n 
US
$
Morbidity cost (women) 
Thyroid
Breast
Colorectum
Stomach
Uterine cervix
Ovary
Liver
Lung
Kidney
0
100
200
300
400
500
600
700
800
900
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010
M
ill
io
n 
US
$
Mortality cost (women)
Breast
Stomach
Leukemia
Lung
Colorectum
Liver
Brain
Uterine cervix
Ovary
NHL
0
200
400
600
800
1,000
1,200
1,400
1,600
1,800
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010
M
ill
io
n 
US
$
Total burden (women)
Breast
Thyroid
Stomach
Colorectum
Leukemia
Lung
Liver
Uterine cervix
Ovary
Brain
Fig. 1.  Economic burden of cancer in Korea by cancer site during 2000-2010. NHL, non-Hodgkin lymphoma.
4th/673 for breast cancer, and from the 18th/26 to the
8th/194 for prostate cancer (data not reported in the tables)
(Tables 5 and 6, Fig. 2).
Discussion
1. Main findings of this study 
Colorectal, thyroid, and breast cancers became more 
significant in terms of economic burden for Korea during
2000-2010. The rise of colorectal cancer was more evident for
the older age group and the opposite was true for thyroid
cancer. In addition, liver and stomach cancers were promi-
nent in the nation during the period. Finally, the share of
mortality cost in the total burden dropped from 71% to 51%
in Korea during 2000-2010, and the relative growths of direct
and morbidity cost were led by colorectal, thyroid, breast,
and prostate cancers during the period. These results show
that the economic burden of cancer in Korea is characterized
by an increasing importance of chronic components. 
2. What is already known on this topic 
The economic burden of cancer in an advanced nation 
centers on breast, colon, lung, and prostate cancers. Indeed,
as medical technology advances and cancer survival 
increases, the share of mortality cost in cancer burden 
registers a graduate fall in the developed world. 
3. What this study adds 
This research presents a very rare analysis of economic
burden by cancer site, gender, age group, and cost compo-
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Table 5. Economic burden in Korea by cancer site, age group in 2000 and 2010 (thousand US$) 
Cancer type ICD-10 0-14 yr (A) 15-69 yr (B) ! 70 yr (C) Rank for A/B/Ccode 2000 2010 2000 2010 2000 2010 2000 2010
Liver C22 43,776 23,809 1,993,174 2,960,679 28,418 129,555 5/1/4 4/1/4
Stomach C16 3,603 46 1,976,338 2,797,811 56,015 247,969 14/2/1 18/2/3
Colorectum C18-C21 10,295 37 784,502 1,923,877 42,367 286,032 8/4/3 19/3/1
Lung C33-C34 20,177 64 1,128,019 1,734,244 54,284 253,344 7/3/2 15/4/2
Thyroid C73 3,524 7,071 240,046 1,639,136 13,497 77,580 15/12/6 8/5/6
Breast C50 43 4,319 524,637 1,614,472 4,231 40,564 21/6/15 11/6/10
Leukemia C91-C95 577,293 466,899 641,730 981,122 4,081 27,152 1/5/16 01/7/13
Brain C69-C72 343,198 366,666 350,613 617,273 3,920 18,510 2/7/17 2/8/17
Pancreas C25 2,780 64 291,896 570,309 9,709 47,922 16/9/8 16/9/8
NHL C82-C85 92,814 61,488 295,933 547,329 4,911 40,612 3/8/14 3/10/9
Uterine cervix C53 6 74 251,202 425,395 5,829 22,199 23/11/13 14/11/15
Kidney C64 49,065 14,517 117,672 353,401 6,231 33,783 4/16/12 5/12/11
Ovary C56 492 5,002 175,717 344,064 3,083 14,856 19/13/19 10/13/20
Mouth C00-C14 584 786 174,734 312,946 6,969 23,956 17/14/10 12/14/14
Gallbladder C23-C24 4,423 11 271,831 261,641 17,123 8,117 10/10/5 21/15/21
Prostate C61 26 55 42,270 173,096 12,926 122,017 22/22/7 17/16/05
Esophagus C15 4,374 0 148,564 167,247 6,510 30,273 11/15/11 23/17/12
Bladder C67 86 32 90,383 166,394 7,061 54,070 20/17/9 20/18/07
MM C90 497 592 46,920 140,699 2,079 19,883 18/21/21 13/19/16
Uterus C54-C55 4 0 90,252 134,039 733 5,612 24/18/22 24/20/22
Skin C43-C44 3,981 5,820 61,862 123,175 2,581 18,464 12/20/20 9/21/18
Larynx C32 3,731 5 75,002 75,495 3,728 15,983 13/19/18 22/22/19
HL C81 35,108 7,830 42,083 42,570 287 1,307 6/23/24 7/23/23
Testis C60,62,63 5,264 8,877 25,180 32,105 433 846 9/24/23 6/24/24
Others 5,481 12,979 71,531 157,980 4,656 20,191 
Total 1,210,624 987,043 9,912,090 18,296,498 301,665 1,560,796 
ICD-10, International Classification of Diseases 10th revision; NHL, non-Hodgkin lymphoma; MM, multiple myeloma; HL,
Hodgkin lymphoma.
nent in Korea during 2000-2010. Most existing literature on
national economic burden has been limited to direct medical
cost, and comprehensive examination of the national 
economic burden by cancer site, gender, age group, and cost
component over a long time span has been limited. 
This research shows that Korea is converging with other
advanced nations in the economic burden of cancer. In terms
of direct cost, breast, colon, lung and prostate cancers, which
ranked in the top four in the United States for 1996, 
Canada for 1998 and New South Wales in Australia for 2004,
constituted the top eight in Korea for 2010, i.e., colorectal 
cancer (first position, 855 million US$), breast cancer (fourth,
673 million US$), lung cancer (fifth, 651 million US$) and
prostate cancer (eighth, 194 million US$). In addition, the
share of mortality cost in the total burden, which dropped
from 73% to 51% in the United States during 1972-2008, 
registered a similar trend in Korea, i.e., a fall from 71% to
51%, albeit during a much shorter period, 2000-2010. Korea’s
convergence with other advanced nations in cancer burden
might reflect their convergence in living standards, the age
structure, health behavior and medical technology during
the past four decades. The rise of Korea’s Gross Domestic
Product per capita relative to the Organisation for Economic
Cooperation and Development average (e.g., from 0.26 to
0.77 during 1980-2012 in terms of Purchasing Power Parity
current international dollars [1]) has been accompanied by
the growing proportion of the elderly population and the rise
of meat consumption. Korea’s share of the population aged
60 years or older, which was 15% in 2009, is likely to reach
21% in 2018, the figure for the developed regions in 2009
[14,17]. The average share of energy intake from meat 
consumption increased from 5.1% to 14.2% in the nation 
during 1970-1993 [19]. This “modified (or westernized)” 
dietary pattern became more robust among younger and
metropolitan residents with more education and higher 
income in the nation during 1998-2005 [20]. Korea’s conver-
gence with other developed nations has been apparent in
medical technology as well, particularly in selective, 
customized cancer treatment [21]. With the establishment of
the National Cancer Center in 2000 and the legislation of the
Cancer Control Act in 2003, the Second 10-Year Plan for 
Cancer Control in Korea during 2006-2015 has contributed
to the rise of 5-year relative cancer survival from 53.7% 
during 2001-2005 to 64.1% during 2006-2010 [22]. These 
economic, demographic, behavioral, technological, and 
sociopolitical changes might have aided in the shift of cancer
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Fig. 2.  Economic burden of cancer in Korea by cost component during 2000-2010. 
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from acute to chronic in Korea. 
Unlike Australia, Canada, and the United States, however,
Korea has been characterized by the continued importance
of stomach and liver cancers during 2000-2010 according to
the results of this work. In terms of the total burden, these
two cancers ranked first and second in 2000 (2,065, 2,036 
million US$), holding the same positions in 2010 (3,114, 3,046
million US$). Indeed, a change in the pattern of economic
burden for major cancers in Korea has been much more 
dramatic than in other advanced nations. For example, it
took 36 years in the United States for the share of mortality
cost to hit 51% (in 2008) from 73% (in 1972). However, the
length of that period was just 10 years for Korea, given that
the statistic for the nation started at 71% in 2000 and arrived
at 51% in 2010. These results suggest that the economic 
burden of cancer in Korea follows the pattern of other 
advanced nations in general but also registers some unique
characteristics affected by its distinctive epidemiological and
sociocultural contexts, e.g., higher sodium intake (regarding
stomach cancer), higher infection of hepatitis B virus (regard-
ing liver cancer), over-diagnosis of thyroid cancer, and 
sudden advent of an aging society (regarding direct/
morbidity cost) [14,17]. With such a rapidly aging popula-
tion, Korea’s average annual rate of economic growth, which
was 9.5% during 2000-2010 [17], might drop to 4.1% during
2011-2020 and decrease further to 2.8% during 2021-2030 [23].
Given these dramatic transitions, two recommendations can
be made for cancer control in Korea. First, greater focus on
primary prevention, including sodium-controlled diet and
hepatitis B vaccination, is needed in Korea. When economic
resources are limited, primary prevention is the most cost-
effective strategy for reducing cancer burden, and this is 
particularly true for a nation like Korea, where gastrointesti-
nal cancer is dominant with widespread bacterial infection
[24]. Second, a more consistent and integrative system of
cost-effective analysis (CEA) on cancer screening and treat-
ment is needed in Korea. At this time, only a quarter of new
screening/treatment technologies are covered by health 
insurance in Korea, largely because its CEA system is neither
consistent nor integrative enough for timely and appropriate
evaluation. More evidence might be helpful in reducing 
cancer burden in Korea. The findings of this study might 
provide good lessons and important policy implications for
all nations striving for rapid economic growth and experi-
encing sudden sociocultural transformations. 
4. Limitations of this study 
For the calculation of the expected value of the future 
income or women’s opportunity cost for housework during
potential years of life lost from a base year, it was presumed
that (1) the participation rate for economic activity and the
employment rate (varying by gender and age group in a
given year) stay the same in the future as in the base year and
(2) the women’s non-participation rate for economic activity
(varying by age group in a given year) remains the same in
the future as in the base year. Modifying these assumptions
might improve the accuracy of estimating mortality cost.
Also, projecting Korea’s cancer burden over 2010-2030 might
provide additional insight into existing literature on cancer
burden. Indeed, comparative analysis of Korea and other 
nations might contribute to more systematic examination of
cancer burden. In addition, the extension of this study into
all main diseases in Korea is expected to further the bound-
ary of knowledge on disease burden. Despite these limita-
tions, this research constructs rich data and presents a rare
comprehensive examination of cancer burden in Korea, a 
nation with the most rapid demographic, socioeconomic, 
behavioral, and technological transformations in the past
four decades.
Conclusion
Incorporation of distinctive epidemiological, sociocultural
contexts into Korea’s cancer control program, with greater
emphasis on primary prevention such as sodium-controlled
diet and hepatitis B vaccination, may be needed. 
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